New immune cells to help stem cell transplant success
Part of Immune system & allergy clinical trials.
This trial tests whether a special type of immune cell (called CD8 regulatory precursors) can help prevent the body from rejecting a stem cell transplant from a donor. It is for patients receiving a stem cell transplant from a related donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You are planning to get a stem cell transplant from a family member (not from an unrelated donor or cord blood)
- You are willing and able to follow the study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
This trial tests a stem cell transplant using a reduced-intensity chemotherapy regimen and a low dose of a drug called cyclophosphamide after the transplant to help prevent graft-versus-host disease (GVHD), a common complication where donor cells attack the recipient's body. It is for people with certain blood cancers or bone marrow disorders who have a suitable donor.
This study looks at special immune cells in the body that may be involved in graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to better understand these cells to improve future treatments for GVHD.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a new treatment using special white blood cells (called Treg cells) to help control graft-versus-host disease (GVHD), a common complication after a stem cell transplant. The goal is to reduce GVHD symptoms without the serious side effects of high-dose steroids.
Hear when a new Graft-versus-host Disease (GVHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.